Researchers recently discovered that the Aethlon hemopurifier captures tumor secreted exosomes that inhibit the ability of the immune system to combat cancer. Based on emerging data, Aethlon believes that the hemopurifier will evolve to become an adjunct treatment standard to enhance the benefit of therapies administered to cancer patients.
The hemopurifier addresses the previous challenge of isolating and identifying low-abundant cancer biomarkers from the complex mixture of substances contained in blood.
James Joyce, chairman and CEO of Aethlon Medical, said: “Beyond our opportunity to enter the cancer therapy market, we need to ensure our intellectual property estate also protects the use of the hemopurifier as an ultra sensitive method to diagnose the earliest stages of cancer.”